Immuno-Biological Laboratories

4570.TPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥1.0bn+3.7% YoY Operating income¥281m+34.4% YoY Net income (owners)¥329m+32.1% YoY Total assets¥2.2bn+16.8% YoY EPS (basic)¥35.33+32.1% YoY

Full financial history and reports →

Stock price4570 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Sep 30 · JST2 filings

12:245% STAKEImmuno-Biological Laboratories · Tsutomu Seito · 15.15% → 13.48%−1.67pp 12:215% STAKEImmuno-Biological Laboratories · Tsutomu Seito · 18.23% → 15.32%−2.91pp

All filings →

Major holders (5%+) · 1

Holder	Stake	Change	Filed
Tsutomu Seito	12.06%	0.00pp	2026-09-30

Each holder's own ratio from its most recent large-shareholding report.